Loading clinical trials...

Effect of a Mobile Health Intervention on Treatment Adherence | Clinical Trials | Clareo Health

COMPLETEDNA

Effect of a Mobile Health Intervention on Treatment Adherence

Effect of an Mobile Health Intervention on Adherence to Antiretroviral Treatment in Adult Patients Living With HIV Compared to Standard Care

NCT05187741•Hospital Civil de Guadalajara

View on ClinicalTrials.gov

Summary

This is a randomized clinical trial across the whole of the patients who attend the HIV Unit of the Hospital Civil Viejo, a sample calculated in 43 patients for each group (intervention and control). Patients who have HIV infection and are starting antiretroviral treatment (ART), who are between 18 and 50 years old and have a mobile device, will be included in the study. The messages will consist of medical appointment reminders and adherence and motivational messages for a period of six months.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Recently diagnosed with HIV infection
•. starting with antiretroviral therapy and haven't taken ART before
•Patients with the status of "lost to follow up" who return to re-initiate ART

Exclusion Criteria

•Patients who are participating in other study
•patients above 18 years old
•Patients who does not have signal phone at their residency
•Those who refuses to participate in the study

Locations (1)

Hospital Civil de Guadalajara "Fray Antonio Alcalde"

Guadalajara, Jalisco, Mexico

Key Dates

Start Date

April 1, 2022

Primary Completion Date

November 15, 2022

Completion Date

November 15, 2022

Last Updated

November 29, 2022

Enrollment

ACTUAL participants

Conditions

HIV I Infection

Interventions

mobile health (mHealth)

DEVICE

Evaluating the Safety and Immunogenicity of MTBVAC

NCT05947890

HIV I InfectionTuberculosis

View study

RECRUITINGNA

Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset

NCT06834113

HIV I InfectionInjection Pain

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 29, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of a Mobile Health Intervention on Treatment Adherence

Inclusion Criteria

Exclusion Criteria

Evaluating the Safety and Immunogenicity of MTBVAC

Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset

Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa